Stocktoria
SHOULDER INNOVATIONS, INC. SI
SHOULDER INNOVATIONS, INC. (SI) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $47.3M at a -85.3% net margin.
Beneish M-score: -2.42 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-10 | UBS | Buy (main) |
| 2026-08-07 | Piper Sandler | Overweight (reit) |
| 2026-08-07 | BTIG | Buy (main) |
| 2026-07-28 | UBS | Buy (init) |
| 2026-05-08 | Piper Sandler | Overweight (reit) |
| 2026-03-11 | BTIG | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.841 |
| Retained earnings / assets | -0.573 |
| EBIT / assets | -0.155 |
| Equity / liabilities | 4.827 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SI | SHOULDER INNOVATIONS, INC. | 4/9 | 7.68 | — | +49.6% |
| TLSI | TriSalus Life Sciences, Inc. | 4/9 | — | — | +53.4% |
| CARL | CARLSMED, INC. | 5/9 | 4.88 | — | +85.9% |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
| SSII | SS Innovations International, Inc. | 4/9 | -0.09 | — | +105.7% |
| APYX | Apyx Medical Corp | 5/9 | -0.11 | — | +9.9% |
| KRMD | KORU Medical Systems, Inc. | 4/9 | -0.06 | — | +22.2% |
FAQ
Is SI financially healthy?
SHOULDER INNOVATIONS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SI pay a dividend?
No, SHOULDER INNOVATIONS, INC. does not currently pay a dividend.
How profitable is SI?
In FY2025, SHOULDER INNOVATIONS, INC. had a net margin of -85.3% and a return on equity of -28.7%.
What is the analyst price target for SI?
The average Wall-Street price target for SHOULDER INNOVATIONS, INC. is $26.25, about 35.7% above the recent price, from 4 analysts (consensus: strong buy).
Is SI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SHOULDER INNOVATIONS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.